Tulobuterol: one-month intravenous safety studies in rats and dogs.
Tulobuterol was given intravenously to rats and dogs at dosages of 1, 5, or 25 mg/kg/day and 0.6, 2, or 6 mg/kg/day, respectively. The no-toxic-effect dosages were 5 mg/kg/day in rats and 6 mg/kg/day in dogs. Two rats died at 25 mg/kg/day. Convulsions, jerking movements, hyperactivity, tremors, hypoactivity and ptyalism were observed in rats given 25 mg/kg/day. Restlessness, ptyalism and hypoactivity were also observed in dogs at 2 and 6 mg/kg/day. Cutaneous and/or mucosal erythema were observed in rats and dogs at all dosages. Increased body weight gain occurred in drug-treated rats and in mid- and high-dose female dogs. Slight elevations in serum creatinine and BUN were seen in rats and dogs at the highest dosages. Heart weights were increased in rats at all dosages after 1 month of treatment and in rats given 25 mg/kg/day after 2 weeks of recovery. There were no treatment-related morphologic changes in either species.
D000818:Animals; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D004285:Dogs; D004435:Eating / Q000187:drug effects; D005260:Female; D006863:Hydrogen-Ion Concentration; D007263:Infusions, Parenteral; D008297:Male; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012472:Salivation / Q000187:drug effects; D013045:Species Specificity; D013046:Specific Gravity; D013726:Terbutaline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity / Q000652:urine; D013997:Time Factors
D001993:Bronchodilator Agents; C010809:tulobuterol; D003404:Creatinine; D013726:Terbutaline